Cornell Law Review Online, Vol. 99, 2013
24 Pages Posted: 16 Mar 2013 Last revised: 3 Jul 2013
Date Written: March 1, 2013
Pharmacy benefit managers (PBMs) save Americans billions of dollars each year by lowering the prices of prescription drugs and the costs of prescription drug coverage. However, as I explain in this Article, mandatory disclosure regulations recently enacted in several states and under the Affordable Care Act threaten to disrupt the cost savings PBMs currently produce for consumers. These regulations require PBMs to disclose competitively-sensitive financial information to various participants in the prescription drug market. Although mandatory disclosure regulations are premised on the idea that PBM clients can only ensure that they are paying a competitive price for PBM services if they know the specifics of PBMs’ financial arrangements with pharmaceutical manufacturers and pharmacies, there is no theoretical or empirical reason to believe mandated disclosure of this information is necessary. Not only are these regulations unnecessary to achieve competitive outcomes, they also impose significant costs on PBMs. The additional disclosure increases both direct costs and litigation costs for PBMs. More importantly, the regulations foster tacit collusion and reduce PBMs’ ability to negotiate discounts with pharmacies and rebates with drug manufacturers. By disrupting competition in the prescription drug market, mandatory disclosure regulations will ultimately increase the prices that consumers pay for prescription drugs.
Keywords: prescription drug market, pharmacy benefit manager, disclosure, transparency
JEL Classification: I1
Suggested Citation: Suggested Citation
Shepherd, Joanna, Is More Information Always Better? Mandatory Disclosure Regulations in the Prescription Drug Market (March 1, 2013). Cornell Law Review Online, Vol. 99, 2013; Emory Legal Studies Research Paper No. 13-245. Available at SSRN: https://ssrn.com/abstract=2234212